BioCryst Pharmaceuticals, Inc.BCRXNASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +40.83% | +56.89% | +49.41% | +36.14% | +209.09% |
| Gross Profit Growth | +36.66% | +54.07% | +49.17% | +37.78% | +216.29% |
| EBITDA Growth | +0.00% | +0.00% | +126.25% | +174.77% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +239.98% | +284.70% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +2.97% | +1.37% | +1.50% | +1.58% | +1.73% |
| Weighted Average Shares Diluted Growth | +2.97% | +4.46% | +6.52% | +6.27% | +5.73% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +398.62% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +385.79% | +0.00% |
| Receivables Growth | +38.84% | +54.15% | +32.60% | +26.04% | +35.09% |
| Inventory Growth | -71.81% | -76.92% | +13.35% | -30.81% | -33.25% |
| Asset Growth | -5.13% | +2.60% | -3.22% | -9.13% | +4.84% |
| Book Value per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Debt Growth | +1.97% | +0.29% | -14.42% | -18.88% | -43.27% |
| R&D Expense Growth | -29.42% | -19.84% | +15.32% | +7.76% | -16.66% |
| SG&A Expenses Growth | +24.99% | +38.62% | +42.67% | +27.55% | +19.03% |